Abstract
FDA on August 3 approved Mavyret, a glecaprevir–pibrentasvir combination product marketed by AbbVie Inc., for the treatment of chronic hepatitis C virus (HCV) infection caused by any of the known viral genotypes. According to FDA, Mavyret is the first product with a recommended 8-week course of
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Paper Title
Journal
Date
